Philip Larsen
Chief Executive Officer Six Peaks Bio
Philip Larsen, MD, PhD, is a visionary leader in metabolic drug development and currently serves as Chief Executive Officer of Six Peaks Bio, a company pioneering next-generation therapies for obesity and metabolic diseases. With over two decades of executive experience in global pharmaceutical R&D, Philip has shaped transformative research strategies across major organizations.
Previously, as Senior Vice President and Global Head of Research & Early Development at Bayer Pharmaceuticals, he oversaw therapeutic innovation from discovery through clinical proof-of-concept. His leadership roles also include Chief Scientific Officer at Grünenthal Group and Sanofi’s German Hub, where he advanced portfolios in cardiometabolic and metabolic diseases, as well as Vice President of Clinical iMed (CVGI) at AstraZeneca, driving clinical-stage pipelines.
Trained as a physician-scientist with an MD and PhD from the University of Copenhagen, Philip uniquely bridges clinical insight with translational research. His expertise spans obesity therapeutics, incretin biology, and metabolic target validation, underpinned by a track record of advancing molecules from bench to bedside.
Seminars
- Integrating myostatin/activin inhibitors with GLP-1 agonists to preserve metabolic health and enhance long-term patient outcomes
- Leveraging biomarkers & phenotyping to guide patient stratification for combination therapies to identify responders to specific mechanisms
- Designing adaptive trials for multi targeted therapies to enable dosing optimisation and combination ratios for improved efficacy and tolerability
Join this session to explore how obesity trials and treatment paradigms must evolve with GLP-1 agonists as the new backbone therapy. Experts will debate optimal approaches for testing combinations and sequencing therapies, addressing critical questions about trial design, phenotypic targeting, and weight rebound mitigation.
- Determining patient-centric cardiometabolic endpoints to extend beyond weight loss while satisfying payer demands
- Combining dual GLP-1 and myostatin inhibitors to reduce muscle mass loss for greater metabolic health and explore composite endpoints that reflect real-world patient priorities to lower trial dropout rates
- Exploring sequential therapy protocols to reduce GI side effects for improved long-term adherence
- Reducing weight cycling by shifting focus from acute weight loss to sustained metabolic outcomes
- Comparing preclinical data on myostatin-only vs. dual myostatin/activin A inhibitors to increased understanding of differentiating factors
- Guiding pharmaceutical partnerships and clinical trial designs for combination optimisation
- Identifying outcomes for patient subset identification in clinical stages
